Abstract
Background Despite the established importance of identifying depression in Parkinson’s disease, our understanding of the factors which place the Parkinson’s disease patient at future risk of depression is limited.
Methods Our sample consisted of 874 patients from two longitudinal cohorts, PPMI and PDBP, with median follow-up durations of 7 and 3 years respectively. Risk factors for depression at baseline were determined using logistic regression. A Cox regression model was then used to identify baseline factors that predisposed the non-depressed patient to develop depressive symptoms that were sustained for at least one year, while adjusting for antidepressant use and cognitive impairment. Common predictors between the two cohorts were identified with a random-effects meta-analysis.
Results We found in our analyses that the majority of baseline non-depressed patients would develop sustained depressive symptoms at least once during the course of the study. Probable REM sleep disorder (pRBD), age, duration of diagnosis, impairment in daily activities, mild constipation, and antidepressant use were among the baseline risk factors for depression in either cohort. Our Cox regression model indicated that pRBD, impairment in daily activities, hyposmia, and mild constipation could serve as longitudinal predictors of sustained depressive symptoms.
Conclusions We identified several potential risk factors to aid physicians in the early detection of depression in Parkinson’s disease patients. Our findings also underline the importance of adjusting for multiple covariates when analyzing risk factors for depression.
Competing Interest Statement
Tarek Antar received a Postbaccalaureate Intramural Research Training Award from National Institute Aging. Andrew Singleton has received grants from the Michael J Fox Foundation for Parkinson's Research, the Department of Defense NETPR Program (Grant IAA-XAG16001- 001-00000), and the Aligning Science Across Parkinson's Initiative. The authors otherwise have no financial interests to report.
Funding Statement
This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, part of the Department of Health and Human Services (project ZO1 AG000949).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants' information was obtained under appropriate written consent and with local institutional and ethical approval. The study protocols were approved at the local institutional review boards, and the participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosure: This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, part of the Department of Health and Human Services (project ZO1 AG000949).
Data Availability
Data from the Parkinson's Progression Markers Initiative (PPMI) was obtained through the Image & Data Archive (https://ida.loni.usc.edu/). Data from the Parkinson's Disease Biomarkers Program (PDBP) was obtained from the Global Parkinson's Genetics Program (https://parkinsonsroadmap.org/gp2/). Analysis scripts are available at https://github.com/GP2code/LongPDDepRisk.
